covid_cell_1

Pharmafile.com’s weekly COVID-19 news round-up

pharmafile | November 25, 2020 | News story | Research and Development  

The coronavirus news this week sees more companies release their coronavirus vaccine results, with Pfizer and BioNTech backing up their promising interim Phase 3 data showing 90% efficacy for their COVID-19 vaccine candidate with a final analysis of the findings, showing an even higher level of efficacy, while the National Research Center for Epidemiology and Microbiology and the Russian Direct Investment Fund (RDIF) have released a statement saying the Sputnik V vaccine for COVID-19 has a 91.4% efficacy after 28 days, and over 95% efficacy 42 days after the first dose.

1. Pfizer/BioNTech’s COVID-19 vaccine shows up to 95% efficacy in final analysis, including in over-65sPublished on 18/11/20

Pfizer and BioNTech have backed up their promising interim Phase 3 data showing 90% efficacy for their COVID-19 vaccine candidate with a final analysis of the findings, showing an even higher level of efficacy, and in crucial sub-populations.

2. FDA approves first at-home coronavirus self-testing kitPublished on 18/11/20

The FDA has issued an Emergency Use Authorization for the first coronavirus self-testing kit for use at home that produces rapid results.

3. Russia’s Sputnik COVID-19 vaccine has 91.4% efficacy after 28 days, new interim data showPublished on 24/11/20

The National Research Center for Epidemiology and Microbiology and the Russian Direct Investment Fund (RDIF) have released a statement saying the Sputnik V vaccine for COVID-19 has a 91.4% efficacy after 28 days, and over 95% efficacy 42 days after the first dose.

4. Five Chinese coronavirus vaccines in overseas clinical trialsPublished on 19/11/20

Five different coronavirus vaccines from China are being tested in Phase 3 trials around the world.

5. Pfizer launches pilot delivery programme for its coronavirus vaccinePublished on 17/11/20

Pfizer is set to launch its first delivery programme for the COVID-19 vaccine it developed with BioNTech. It will be located in multiple sites across America; the company said it has selected New Mexico, Tennessee, Rhode Island and Texas for the programme because of their differences in size and immunisation infrastructure.

Related Content

No items found

Latest content